Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold

Royalty Pharma (NASDAQ:RPRX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Sunday.

Several other research firms have also weighed in on RPRX. Morgan Stanley assumed coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They set an "overweight" rating and a $51.00 price objective on the stock. Citigroup restated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $47.33.

Royalty Pharma Stock Up 1.7%

Shares of RPRX stock opened at $35.87 on Friday. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.68. Royalty Pharma has a 1 year low of $24.05 and a 1 year high of $36.32. The firm's fifty day moving average price is $33.47 and its two-hundred day moving average price is $31.59. The firm has a market capitalization of $20.17 billion, a P/E ratio of 19.39, a PEG ratio of 1.84 and a beta of 0.48.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.07. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. The firm had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. On average, equities analysts predict that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Louisbourg Investments Inc. acquired a new position in Royalty Pharma in the 1st quarter valued at about $28,000. MassMutual Private Wealth & Trust FSB grew its stake in Royalty Pharma by 76.4% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 414 shares during the last quarter. Riverview Trust Co grew its stake in Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,186 shares during the last quarter. Summit Securities Group LLC acquired a new position in Royalty Pharma in the 1st quarter valued at about $36,000. Finally, WPG Advisers LLC acquired a new position in Royalty Pharma in the 1st quarter valued at about $39,000. 54.35% of the stock is currently owned by institutional investors and hedge funds.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.